KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Sales (2016 - 2025)

NovoCure's Return on Sales history spans 12 years, with the latest figure at 0.14% for Q4 2025.

  • For Q4 2025, Return on Sales rose 27.0% year-over-year to 0.14%; the TTM value through Dec 2025 reached 0.21%, up 7.0%, while the annual FY2025 figure was 0.21%, 7.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.14% at NovoCure, up from 0.22% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.03% in Q1 2021 and bottomed at 0.46% in Q2 2023.
  • The 5-year median for Return on Sales is 0.22% (2024), against an average of 0.24%.
  • The largest annual shift saw Return on Sales plummeted -40bps in 2023 before it rose 27bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.2% in 2021, then plummeted by -46bps to 0.29% in 2022, then dropped by -21bps to 0.35% in 2023, then decreased by -16bps to 0.41% in 2024, then soared by 66bps to 0.14% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Return on Sales are 0.14% (Q4 2025), 0.22% (Q3 2025), and 0.25% (Q2 2025).